Servier Ventures
◆ Fund Size
$220M
◆ Check Size
◆ Location
France
◆ Activity
Statusactively investing
◆ Links
◆ Share this fund
◆ Investment Thesis
Early-stage biotech investment in oncology and neurology, focusing on late preclinical assets where Servier can provide scientific, clinical, industrial expertise and network access. Strategic fund aligned with Servier's drug development capabilities.
◆ About Servier
Servier Ventures is a €200m ($234m) corporate venture capital fund launched by French pharmaceutical company Servier to invest in early-stage biotech startups. The fund targets oncology and neurology-focused companies, initially in Europe, with plans to expand to the US and Asia. It aims to bridge the funding gap between early-stage research and late-stage development activities.
◆ Sectors
◆ Stages
◆ Geography Focus
◆ Team
| Name | Title | Role | Links |
|---|---|---|---|
| Alexis Vandier | Global Head of Servier Ventures | — | |
| Asmae Riadi | Investment Director, Servier Ventures | — |
◆ Notable Investments
◆ Traits
Leads rounds
Co-invests
◆ FAQ
What does Servier Ventures invest in?
Servier Ventures invests in Biotech, Drug Discovery and Diagnostics at the seed and series-a stages.
Which geographies does Servier Ventures focus on?
Servier Ventures focuses on Europe, and is headquartered in France.
What is Servier Ventures's typical check size?
Servier Ventures typically writes checks of $5.9M to $11.8M.